Dermata Therapeutics, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Subsequent Events (Details Narrative) - USD ($)			1 Months Ended
Subsequent Events (Details Narrative) - USD ($)	Jan. 13, 2025	Jan. 01, 2025	Feb. 28, 2025	Jan. 31, 2025	Jan. 21, 2025	Dec. 31, 2024	Dec. 31, 2023
Common shares outstanding						2,517,768	261,998
2021 Plan [Member]
Common shares outstanding						2,517,768
Subsequent Event [Member] \| September 2024 PIPE
Pre-Funded Warrants exercised				905,000,000,000
Subsequent Event [Member] \| 2021 Plan [Member]
Shares increased		125,888
Shares issuable increased		152,563
Stock options award granted	152,500
Exercise price	$ 1.38
Subsequent Event [Member] \| Purchase Agreement [Member]
Purchase agreement description					(i) 1,935,412 shares (the “Shares”) of the Company’s Common Stock, (ii) pre-funded warrants (“Pre-Funded Warrants”) to purchase up to 72,468 shares of Common Stock, at an exercise price of $0.001 per share, and (iii) warrants (the “Warrants”) to purchase up to 2,007,880 shares of Common Stock at an exercise price of $1.27 per share. The purchase price per Share and accompanying Warrant was $1.27 and the purchase price per Pre-Funded Warrant and accompanying Warrant was $1.269
Insiders purchased shares and warrants					1,220,476
Insiders purchased common stock					1,220,476
Purchase price					$ 1,550,000
Net proceeds					$ 2,400,000
Pre-Funded Warrants exercised			72,468,000,000
Common Stock shares outstanding increased			72,468,000,000